Detecting melanoma early, without a biopsy
FORT COLLINS, COLO. - Melanoma is a form of skin cancer that becomes dangerous when it spreads, but is treatable in its early stages. Doctors diagnose melanoma by cutting away a piece of a suspicious skin lesion -- a procedure known as a biopsy -- and testing it for malignant cells.
It's an imperfect, invasive method that Colorado State University researcher Jesse Wilson wants to improve. His goal is to make early detection of melanoma faster, cheaper and less invasive than a biopsy.
An assistant professor in the Department of Electrical and Computer Engineering and in the School of Biomedical Engineering, Wilson's expertise is in pushing the boundaries of biomedical optics. He has received a one-year, $30,000 grant from the Colorado Clinical and Translational Sciences Institute to develop a new microscope that can distinguish between benign and malignant pigmented skin lesions, without the need for biopsy.
If his idea works, it could lead to low-cost, in-vivo imaging of melanin, the skin pigment that's made by cells called melanocytes, which can become cancerous and lead to melanoma.
The grant is through the CCTSI's "CO-Pilot" program, which provides start-up funds for early-career researchers embarking on multidisciplinary new ideas. Wilson, who did his undergraduate, master's and Ph.D. work at CSU, has returned to campus as a faculty member to continue applying cutting-edge biomedical optics to early cancer detection.
The CO-Pilot is funding Wilson's development of an experimental microscope that uses a technology called pump-probe, which can provide contrast between normal tissue and melanoma without stains or dyes.
Pump-probe is a type of multiphoton microscopy, an established technique used for deep imaging of living tissue. In standard multiphoton microscopy, an extremely short laser pulse is used to excite fluorescent molecules in the sample, which can then be detected when they light up.
In pump-probe, excited molecules are detected not through fluorescence, but through their interactions with a second laser pulse. This allows pump-probe to distinguish molecules based on their absorption properties, which provide strong contrast between different types of melanin.
Pump-probe microscopes that can detect melanoma were developed in the lab of Warren Warren at Duke University, where Wilson completed his postdoctoral training. However, these microscopes require a short-pulse laser source that costs upwards of $300,000 - a major barrier to commercializing the technology for widespread use.
That's the problem Wilson will tackle with the CO-Pilot grant. He is designing a pump-probe microscope that can distinguish between benign and malignant melanoma in vivo, but built around a simpler laser source that's already widely used in telecommunications applications to encrypt voice communications. That laser only costs about $5,000, and would make the pump-probe technology more realistic for melanoma applications.
Wilson will work with Ali Pezeshki, associate professor in ECE and mathematics, on the signal processing that will be central to constructing images with the new microscope. He also plans to collaborate with Dan Gustafson, director of research at the Flint Animal Cancer Center.
Wilson's lab is also pursuing other pump-probe applications, including imaging cytochromes, molecules involved in metabolic activities that can't be imaged with conventional techniques.
Related Melanoma Articles:
Immunity against melanoma is only skin deep
Researchers at Dartmouth's Norris Cotton Cancer Center find that unique immune cells, called resident memory T cells, do an outstanding job of preventing melanoma in patients who develop the autoimmune disease, vitiligo.
Researchers document how melanoma tumors form
University of Iowa researchers have documented in continuous, real time how melanoma cells form tumors.
New driver, target in advanced mucosal melanoma
A University of Colorado Cancer Center study published March 15, 2017, in the journal Melanoma Research uses the unique resource of over 600 melanoma samples collected at the university to demonstrate, for the first time, novel mutations involved in mucosal melanoma, paving the way for therapies to treat this overlooked subtype.
NIH study reveals how melanoma spreads
Newly identified genes and genetic pathways in primary melanoma -- a type of skin cancer -- could give researchers new targets for developing new personalized treatments for melanoma, and potentially other cancers.
Melanoma research breakthrough gives hope to treatment
A QUT-driven project has identified the way in which melanoma cells spread, opening up new pathways to treatment via drugs to 'turn off' the invasive gene.
Study examines melanoma incidence, death
A new research letter published online by JAMA Dermatology updates information on trends in melanoma incidence and death in the United States since 2009.
Research providing promising new treatments for melanoma
In a paper published online Nov. 30, 2016, in Melanoma Management, Adam Riker, M.D., Professor of Surgery and Chief of Surgical Oncology at LSU Health New Orleans School of Medicine, reviews approaches to manage melanoma, including one tested at LSU Health New Orleans that provoked a complete response in a patient with a long history of the disease.
A protein that defines the melanoma blueprint
The latest study of the Melanoma Group at the Spanish National Cancer Research Centre describes the roles of CPEB4; a protein that is crucial for melanoma cell survival.
Nanotechnology supports treatment of malignant melanoma
Changes in the genetic make-up of tissue samples can be detected quickly and easily using a new method based on nanotechnology.
Colorado State University Professor Jesse Wilson has received a one-year, $30,000 grant from the Colorado Clinical and Translational Sciences Institute to develop a new microscope that can distinguish between benign and malignant pigmented skin lesions, without the need for biopsy.
More Melanoma News and Melanoma Current Events
Related Melanoma Reading: